The frequency of interval surveillance in the adult hematopoietic | 21175
Journal of Cell Science & Therapy

Journal of Cell Science & Therapy
Open Access

ISSN: 2157-7013

The frequency of interval surveillance in the adult hematopoietic stem cell transplant survivor

International Conference & Exhibition on Cell Science & Stem Cell Research

29 Nov - 1 Dec 2011 Philadelphia Airport Marriott, USA

Jill Beavers-Kirby

Scientific Tracks Abstracts: J Cell Sci Ther

Abstract :

Cancer treatments for hematologic maligna ncies can include radiation, chemotherapy, immunosuppression, stem cell transplant, and targeted biological therapies. Th ese therapies can cause long-term side eff ects that may negatively aff ect quality of life. Many of these late eff ects are modifi able when a proactive systematic plan of prevention and surveillance is implemented. Th is plan is most eff ective when factors such as past treatments, chromosomal prognostic factors, comorbid health conditions, and lifestyle behaviors are considered. A survivorship care plan specifi c for cancer survivors who have undergone a hematopoietic stem cell transplant (HSCT) would enhance the ability of clinicians to monitor for these late eff ects. Th e Center for International Blood and Marrow Transplant Research, the European Group for Blood and Marrow Transplantation, and the American Society for Blood and Marrow Transplant have recommended that a HSCT-specifi c survivorship care plan include 6-month, 12-month, and annual assessments of physical and psychosocial well-being including preventive screenings unique to the HSCT survivor. Th is quality improvement study described the frequency of documentation of the recommended cancer survivorship guidelines by oncology clinicians in the medical records of adult HSCT survivors at 12 and 24 months post-transplant in one comprehensive cancer center. Th is retrospective chart review found that only three of the 29 recommended guidelines were documented as being completed in more than 50% of the charts at 12 and 24 months. Furthermore, the data indicated that the remaining indicators were documented in less than 50% of the charts at both 12 and 24 months. Th ese fi ndings were used to inform the oncology clinicians of the need for adherence to re commended guidelines and in the planning of a hematology and transplant survivorship clinic for individuals who have completed the acute phase of their cancer treatment.

Biography :

Jill Beavers-Kirby received her B.S. in Nursing from the University of Phoenix in 2001. She received her M.S. in Nursing with a concentration as an Acute Care Nurse Practitioner from Wright State University in 2006. She graduated with her Doctorate of Nursing Practice from the Ohio State University in 2011. Her research interests include improving outcomes of cancer survivors of hematologic malignancies